Lannett Reports Insulin Glargine Trial Success

Ready To Present Trial Design For Lantus Rival To FDA

 
• By Akriti Seth
  
Clinical_Trial
Lannett has announced positive results from a Phase I trial for biosimilar insulin glargine developed with HEC • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products